Ionis Pharmaceuticals Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Ionis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ionis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Ionis Pharmaceuticals.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, February, 24th. The company reported ($2.44) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.24 by $2.68. Ionis Pharmaceuticals had a net margin of 7.82% and a trailing twelve-month return on equity of 6.57%.
View Ionis Pharmaceuticals' earnings history.

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IONS shares have increased by 8.7% and is now trading at $53.41.
View which stocks have been most impacted by COVID-19.

Ionis Pharmaceuticals updated its FY 2021 Pre-Market earnings guidance on Wednesday, February, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600 million, compared to the consensus revenue estimate of $781.31 million.

13 Wall Street analysts have issued 12 month price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $34.00 to $91.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $61.90 in the next year. This suggests a possible upside of 15.9% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of IONS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.97%), Price T Rowe Associates Inc. MD (9.38%), Clearbridge Investments LLC (4.95%), JPMorgan Chase & Co. (1.34%), First Trust Advisors LP (0.99%) and Northern Trust Corp (0.59%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Renaissance Technologies LLC, Clearbridge Investments LLC, Dowling & Yahnke LLC, Sei Investments Co., AJO LP, Pinnacle Associates Ltd., and Hsbc Holdings PLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals or view top insider-selling stocks.

IONS stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, JPMorgan Chase & Co., PFM Health Sciences LP, Morgan Stanley, Alyeska Investment Group L.P., Alyeska Investment Group L.P., Nuveen Asset Management LLC, and Nikko Asset Management Americas Inc..
View insider buying and selling activity for Ionis Pharmaceuticals or or view top insider-buying stocks.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IONS stock can currently be purchased for approximately $53.41.

Ionis Pharmaceuticals has a market capitalization of $7.47 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis.

Ionis Pharmaceuticals employs 817 workers across the globe.

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Ionis Pharmaceuticals is headquartered at 2855 GAZELLE COURT, CARLSBAD CA, 92010.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200 or via email at [email protected]